CTX131
CRSP-ONC-005
Phase 2 mab completed
Quick answer
CTX131 for Clear Cell Renal Cell Carcinoma is a Phase 2 program (mab) at CRISPR Therapeutics AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- CRISPR Therapeutics AG
- Indication
- Clear Cell Renal Cell Carcinoma
- Phase
- Phase 2
- Modality
- mab
- Status
- completed